Every Form 4 that Elanco Animal Health Incorporated (ELAN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ELAN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELAN filings page.
Elanco Animal Health’s president and CEO Jeffrey N. Simmons reported an acquisition of derivative equity compensation. On January 23, 2026, he received 113.4934 deferred stock units at a reference price of $24.4 per unit, increasing his holdings to 18,959.0151 deferred stock units.
Each deferred stock unit gives the right to receive either one share of Elanco common stock or the cash equivalent. These units will settle in cash or shares after his employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Rajeev A. Modi reported a routine equity compensation transaction. On 01/23/2026, he was awarded 57.9762 deferred stock units at a reference price of $24.4 per unit, increasing his beneficial holdings of these units to 7,538.3256, held directly.
The deferred stock units each represent the right to receive either one share of Elanco common stock or the cash equivalent. They will settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Robert M. VanHimbergen, EVP and CFO, reported an acquisition of derivative securities. On January 23, 2026, he acquired 7.8029 deferred stock units at a reference price of $24.4 per unit.
Following this transaction, he beneficially owned 15.915 deferred stock units directly. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent and will settle in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Rajeev A. Modi reported an award of deferred stock units. On 01/09/2026, he acquired 60.2735 deferred stock units at a value of $23.47 per unit, classified as a derivative security and held directly.
Following this transaction, Modi beneficially owned a total of 7,480.3494 deferred stock units. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and these units settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Robert M. VanHimbergen, EVP and CFO, reported a small compensation-related equity transaction. On 01/09/2026 he acquired 8.1121 deferred stock units at a reference price of $23.47 per unit, as disclosed on a Form 4.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and the units settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan. After this transaction, he beneficially owns 8.1121 deferred stock units directly.
Elanco Animal Health Inc. CEO Jeffrey N. Simmons, who also serves as president and director, reported an acquisition of deferred stock units under a company plan. On January 9, 2026, he was credited with 117.9906 deferred stock units at a reference price of $23.47 per unit, bringing his total holdings to 18,845.5217 deferred stock units.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units are designed to settle in cash or shares after employment ends or in a specified future year, in line with the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health director defers fees into stock units. Director Kapila K. Anand converted a portion of her cash director fees into deferred stock units under Elanco's Directors' Deferral Plan on December 31, 2025. She received 381.1312 Deferred Stock Units, each economically equivalent to one share of Elanco common stock, based on the closing share price of $22.63 on the grant date. Following this transaction, she held a total of 8,894.7414 deferred stock units, which will be settled in Elanco common stock when she separates from the Board of Directors.
Elanco Animal Health Inc. insider Jeffrey N. Simmons, the company’s President, CEO and Director, reported an acquisition of derivative securities in the form of deferred stock units on 12/26/2025. The filing shows he acquired 122.5327 deferred stock units tied to Elanco common stock at a derivative price of $22.6 per unit. Following this transaction, he beneficially owns 18,727.5311 deferred stock units directly.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units are scheduled to settle in cash or shares of Elanco common stock after termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive reports deferred stock unit grant. On 12/26/2025, an officer of Elanco Animal Health Inc. acquired 62.5938 deferred stock units under the company’s Executive Deferral and Stock Match Plan. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. Following this transaction, the reporting person beneficially owned 7,420.0759 deferred stock units, which will settle in cash or shares after employment ends or in a specified future year. The officer’s title is Executive Vice President U.S. Pet Health and Global Digital Transformation.
Elanco Animal Health Inc director reports charitable stock gift. Director R. David Hoover reported a transaction dated 12/19/2025 involving Elanco common stock. The filing shows that a revocable trust associated with him disposed of 60,000 shares as a gift to a charitable trust at a reported price of $0 per share.
After this gift, he is shown as beneficially owning 150,000 shares indirectly through a revocable trust, 106,773 shares directly, and 15,920 shares indirectly through the Suzanne A. Hoover Revocable Trust. This reflects a shift in how part of his holdings are allocated, with shares redirected to charitable purposes while maintaining substantial ownership interests.
Elanco Animal Health Inc. director Lawrence Kurzius reported an open-market purchase of company stock. On 12/12/2025, he bought 10,000 shares of Elanco common stock at a price of $21.3 per share. Following this transaction, his directly held beneficial ownership increased to 131,773 shares of Elanco common stock. The filing indicates that it was submitted for one reporting person, reflecting Kurzius’s role as a director of the company.
Elanco Animal Health Inc. officer Rajeev A. Modi reported acquiring additional deferred stock units tied to the company’s common stock. On 12/12/2025, he acquired 66.4453 deferred stock units at a price of $21.29 per unit, increasing his directly held deferred stock units to 7,357.4821.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, with settlement following termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc. reported an insider equity transaction by its president, CEO and director, Jeffrey N. Simmons. On 12/12/2025 he acquired 130.0723 deferred stock units at $ 21.29 per unit, increasing his holdings to 18,604.9984 deferred stock units, held directly. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and these units settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation, reported an insider purchase of company stock. On December 11, 2025, he acquired 4,500 shares of Elanco common stock at a price of $21.33 per share.
After this transaction, Modi directly beneficially owns 123,082 Elanco shares. This total includes 1,579 shares acquired on January 31, 2025 and 205 shares acquired on April 30, 2025 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan.
Elanco Animal Health Inc. executive Robert M. VanHimbergen, the company’s EVP and CFO, reported buying 6,950 shares of common stock on December 11, 2025. The shares were purchased at a weighted average price of $21.6441 per share, with individual trades executed between $21.60 and $21.70 per share.
Following this transaction, he beneficially owns 124,233 shares of Elanco common stock held directly. The reported balance includes 7,426 shares that were previously reported but inadvertently omitted from his prior reported holdings.
Elanco Animal Health Inc. President, CEO and Director Jeffrey N. Simmons reported buying 22,000 shares of Elanco common stock on December 11, 2025. The shares were purchased in multiple transactions at a weighted average price of $21.7498 per share, with individual trade prices ranging from $21.739 to $21.75.
After this transaction, Simmons beneficially owned 167,000 shares held indirectly through a revocable trust and 1,802,380 shares held directly. The direct holdings include 1 share acquired on April 30, 2025 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan.
Elanco Animal Health Inc. reported an insider equity transaction by its President, CEO and Director, Jeffrey N. Simmons. On 11/28/2025, Simmons acquired 119.0047 deferred stock units tied to Elanco common stock at a reference price of $23.27 per unit.
After this transaction, Simmons beneficially owned 18,474.9261 deferred stock units, held directly. Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent.
The units are part of the company’s Executive Deferral and Stock Match Plan and will settle in cash or shares after Simmons’ termination of employment or in a specified future year, according to the plan’s terms.
Elanco Animal Health executive Rajeev A. Modi reported an automatic award of deferred stock units tied to company stock. On 11/28/2025, he acquired 60.7916 deferred stock units at a reference price of $23.27. After this transaction, he beneficially owns 7,291.0368 derivative securities in the form of deferred stock units held directly.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. These units are scheduled to settle in cash or shares of common stock after Modi’s employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan. Modi serves as Executive Vice President U.S. Pet Health and Global Digital Transformation, and this filing reflects his ongoing equity-based compensation.
Elanco Animal Health Inc. director Kapila K. Anand reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, Anand acquired 10,314 shares of Elanco common stock at a stated price of $0, reflecting a board compensation grant rather than a market purchase. After this grant, Anand beneficially owned 94,973 shares of Elanco common stock in direct ownership. The filing notes that this grant is part of the standard annual equity award program for non-employee members of the company’s Board of Directors.
Elanco Animal Health Inc. director reports equity grant. A non-employee member of Elanco’s Board of Directors reported receiving a grant of 10,314 shares of common stock on 11/28/2025 as an annual equity award, structured as deferred stock units with a stated price of $0 for reporting purposes. Following this award, the director beneficially owns 12,853 shares of Elanco common stock in direct ownership. The transaction was reported on a Form 4 as a routine board compensation grant.
Elanco Animal Health Inc. director equity grant reported
A director of Elanco Animal Health Inc. reported receiving an annual equity award on 11/28/2025. The filing shows an award of 10,314 shares of common stock, recorded at a price of $0 as a grant of deferred stock units to a non-employee member of the Board of Directors. Following this grant, the director beneficially owns 88,714 shares of Elanco common stock in direct ownership. This is a routine Form 4 disclosure of director compensation in equity rather than a cash transaction.
Elanco Animal Health Inc. reported an equity award to one of its directors. On 11/28/2025, director Kirk P. McDonald received a grant of 10,314 shares of common stock in the form of deferred stock units as an annual equity award for non-employee board members, at a stated price of $0 per share.
Following this award, McDonald beneficially owns 88,714 shares of Elanco common stock in direct ownership. The filing reflects standard board compensation and does not describe any cash transaction for the company.
Elanco Animal Health Inc. director equity grant reported
A director of Elanco Animal Health Inc. reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, the reporting person acquired 10,314 shares of common stock at a stated price of $0, reflecting a board compensation grant rather than an open‑market purchase. Following this award, the director beneficially owned 121,773 shares of Elanco common stock in direct ownership. The grant is described as an annual equity award to each non‑employee member of the company’s board of directors.
Elanco Animal Health Inc. director equity grant reported
A director of Elanco Animal Health Inc. (ELAN) reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock at a stated price of $0, reflecting a board compensation grant rather than an open-market purchase. Following this transaction, the director beneficially owns 89,714 shares of Elanco common stock held directly.
The filing notes that this award is part of the regular annual equity compensation provided to non‑employee members of Elanco’s Board of Directors, aligning director pay with shareholder interests through stock-based compensation.
Elanco Animal Health Inc. director R. David Hoover reported an equity grant tied to his board service. On 11/28/2025, he received 10,314 shares of common stock as an annual equity award in the form of deferred stock units at a stated price of $0, reflecting a non-cash grant for a non-employee director. After this grant, he beneficially owns 106,773 shares of Elanco common stock directly and an additional 210,000 shares through a Revocable Trust and 15,920 shares through the Suzanne A. Hoover Revocable Trust. The filing is made as a Form 4 by a single reporting person in his capacity as a director.
Elanco Animal Health Inc. reported that a board director received an annual equity grant in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock-equivalent deferred units at a stated price of $0 as an equity award for non-employee members of the Board of Directors. Following this grant, the director beneficially owns 84,813 shares of Elanco common stock in direct form. These awards align the director’s compensation more closely with long-term shareholder value through stock-based incentives.
Elanco Animal Health director reports equity grant
A director of Elanco Animal Health Inc. reported receiving an annual equity award in the form of deferred stock units. On 11/28/2025, the director acquired 10,314 shares of common stock at a reported price of $0, reflecting that this was an equity grant rather than an open‑market purchase. Following this transaction, the director beneficially owned 91,278 shares of Elanco common stock in direct ownership. The award is described as part of the regular annual equity compensation for non‑employee members of the company’s Board of Directors.
Elanco Animal Health Inc. (ELAN) reported an insider equity award for a member of its Board of Directors. On 11/28/2025, director Michael J. Harrington received 10,314 shares of common stock, recorded at a price of $0 per share, reflecting a grant rather than a market purchase. Following this transaction, he beneficially owned 109,577 shares of Elanco common stock in direct ownership. The company explains that this grant represents deferred stock units issued as an annual equity award to each non-employee member of the Board of Directors, aligning director compensation with shareholder interests through stock-based incentives.
Elanco Animal Health Inc. (ELAN) reported a Form 4 filing for executive officer Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation. On 11/14/2025, he acquired 67.0754 deferred stock units at a price of $21.09 per unit. Following this transaction, he beneficially owns 7,230.2452 deferred stock units, held directly.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. According to the company’s Executive Deferral and Stock Match Plan, these deferred stock units will settle in cash or shares after employment ends or in a specified future year.
Elanco Animal Health Inc. executive Jeffrey N. Simmons, the company’s President, CEO and Director, reported a new equity-related award. On 11/14/2025, he acquired 131.3058 deferred stock units at a reference price of $21.09 per unit. After this transaction, he beneficially owned 18,355.9214 derivative securities, held directly. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and these units are designed to settle in cash or shares following termination of employment or during a specified future year under the Executive Deferral and Stock Match Plan.
Elanco Animal Health (ELAN) reported that President, CEO and Director Jeffrey N. Simmons acquired 125.0221 deferred stock units on 10/31/2025 at $22.15 per unit. Following this transaction, he beneficially owns 18,224.6156 derivative securities, held as direct ownership.
Each deferred stock unit represents the right to receive one share of common stock or the cash equivalent. These units settle in cash or shares following termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health (ELAN) officer Rajeev A. Modi reported a routine insider transaction on a Form 4. On 10/31/2025, he acquired 63.8655 Deferred Stock Units (DSUs) in a transaction coded “A.” Following this activity, he beneficially owned 7,163.1698 derivative securities, held directly. The filing lists a $22.15 price for the derivative security. Each DSU represents the right to receive one share of Elanco common stock or the cash equivalent, and DSUs settle in cash or shares following termination of employment or during a specified future year in accordance with the Executive Deferral and Stock Match Plan.